Unknown

Dataset Information

Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.


ABSTRACT:

Background

Mutational inactivation in cancer of key apoptotic pathway components, such as TP53/p53, undermines cytotoxic therapies that aim to increase apoptosis. Accordingly, TP53 mutations are reproducibly associated with poor treatment outcomes. Moreover, cytotoxic treatments destroy normal stem cells with intact p53 systems, a problem especially for myeloid neoplasms, as these cells reverse the low blood counts that cause morbidity and death. Preclinical studies suggest that noncytotoxic concentrations of the DNA methyltransferase 1 (DNMT1) inhibitor decitabine produce p53-independent cell-cycle exits by reversing aberrant epigenetic repression of proliferation-terminating (MYC-antagonizing) differentiation genes in cancer cells.

Methods

In this clinical trial, patients

SUBMITTER: Saunthararajah Y 

PROVIDER: S-EPMC4362268 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature